EMA Authorised: Takhzyro (lanadelumab) — Takeda Pharmaceuticals International AG Ireland Branch

View source ↗

Summary

The EMA authorised lanadelumab (Takhzyro) for hereditary angioedema, with orphan medicine designation and accelerated assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Takhzyro (lanadelumab)

Snippet

Status: Authorised. Therapeutic area: Angioedemas, Hereditary. MAH: Takeda Pharmaceuticals International AG Ireland Branch. Decision date: 25/04/2025. Orphan medicine. Accelerated assessment